Latest in Pulmonary News

Latest in Pulmonary News2018-12-07T09:40:11+00:00

Add Corticosteroids to Your Arsenal for the treatment of Inpatient Community-Acquired Pneumonia.

Corticosteroids were both beneficial and cost-effective for hospitalized adults with severe CAP. Hospitalized people with non-severe CAP may also benefit from corticosteroid therapy, but with no survival advantage

In 2015, results of two randomized trials showed that systemic corticosteroids were beneficial for some hospitalized patients with community-acquired pneumonia (CAP; NEJM JW Gen Med Mar 15 2015 and JAMA 2015; 313:677; NEJM JW Gen Med Mar 1 2015 and Lancet 2015; 385:1511). Now, two new meta-analyses — one by the Cochrane Library, and one by the Infectious Diseases Society of America (IDSA) — address whether CAP patients should receive systemic corticosteroids routinely.

These meta-analyses suggest that low-dose (≈40 mg), short-course (3–7 days) systemic corticosteroids should be strongly considered for hospitalized adults with severe CAP. These results do not apply to outpatients with CAP or to inpatients with hospital-acquired pneumonia or ventilator-associated pneumonia. Several ongoing randomized trials probably will clarify steroid use further for pneumonia indications.

Source:
The Cost-effectiveness of Corticosteroids for the treatment of Community-Acquired Pneumonia
Chest. 2018 Nov 15. pii: S0012-3692(18)32727-2. doi: 10.1016/j.chest.2018.11.001.
https://www.ncbi.nlm.nih.gov/pubmed/30448195?dopt=Abstract

0/5 (0 Reviews)

Home oxygen therapy for COPD: Does it matter whether the patient is hypoxemic? Evidence vs Reality

Home oxygen therapy for COPD: Does it matter whether the patient is hypoxemic? Evidence vs Reality?

Long-term oxygen therapy (LTOT) is given to improve survival time in people with COPD and severe chronic hypoxemia at rest. The efficacy of oxygen therapy for breathlessness and health-related quality of life (HRQOL) in people with COPD and mild or no hypoxemia who do not meet the criteria for LTOT has not been established. Scientific evidence for its benefits of LTOT dates back to the 1980s when two randomized controlled trials showed prolonged survival in COPD-patients undergoing LTOT for at least 15 hours/day. In contrast, the potential benefits of LTOT in non-COPD-patients has not been well researched and the recommendations for its application are primarily extrapolated from trials on COPD-patients.

Recent Cochrane analysis found that oxygen can relieve breathlessness when given during exercise to mildly hypoxaemic and non-hypoxaemic people with chronic obstructive pulmonary disease who would not otherwise qualify for home oxygen therapy. Findings show that COPD patients without severe hypoxemia undergoing oxygen therapy during exercise training over time do not achieve better exercise capacity or health-related quality of life compared with placebo.

However, LTOT has a beneficial effect on quality of life, dyspnea, and exercise capacity in patients with COPD and exertional hypoxemia.

Source:
Oxygen for breathlessness in patients with chronic obstructive pulmonary disease who do not qualify for home oxygen therapy
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006429.pub3/full

J Bras Pneumol. 2018 Sep-Oct;44(5):390-397. doi: 10.1590/S1806-37562017000000019.
Impact of adherence to long-term oxygen therapy on patients with COPD and exertional hypoxemia followed for one year.
https://www.ncbi.nlm.nih.gov/pubmed/30517340

0/5 (0 Reviews)

Latest in Pulmonary Research

  1. Kammerl, IE, Caniard, A, Merl-Pham, J, Ben-Nissan, G, Mayr, CH, Mossina, A et al.. Dissecting the molecular effects of cigarette smoke on proteasome function. J Proteomics. 2018; :. doi: 10.1016/j.jprot.2018.12.015. PubMed PMID:30557664 .
  2. Chin, AJ, Fischione, AD, Shilian, R, Walter, LM, Ratay, SM, Bejanishvili, TY et al.. Tolerance of Rib Raising Among Hospitalized Patients: A Pilot Study. J Am Osteopath Assoc. 2018; :. doi: 10.7556/jaoa.2019.003. PubMed PMID:30556829 .
  3. Gloeckl, R, Osadnik, C, Bies, L, Leitl, D, Koczulla, AR, Kenn, K et al.. Comparison of continuous flow versus demand oxygen delivery systems in patients with COPD: A systematic review and meta-analysis. Respirology. 2018; :. doi: 10.1111/resp.13457. PubMed PMID:30556614 .
  4. Savage, CC, Dixey, PHA, Pennington, C, Dodd, JW. Visual rating assessment of cerebral atrophy and its relationship with cognitive function in chronic obstructive pulmonary disease. BMJ Open Respir Res. 2018;5 (1):e000310. doi: 10.1136/bmjresp-2018-000310. PubMed PMID:30555707 PubMed Central PMC6267327.
  5. Xu, H, Ling, M, Xue, J, Dai, X, Sun, Q, Chen, C et al.. Exosomal microRNA-21 derived from bronchial epithelial cells is involved in aberrant epithelium-fibroblast cross-talk in COPD induced by cigarette smoking. Theranostics. 2018;8 (19):5419-5433. doi: 10.7150/thno.27876. PubMed PMID:30555555 PubMed Central PMC6276085.
  6. Bräunlich, J, Wirtz, H. Nasal high-flow in acute hypercapnic exacerbation of COPD. Int J Chron Obstruct Pulmon Dis. 2018;13 :3895-3897. doi: 10.2147/COPD.S185001. PubMed PMID:30555226 PubMed Central PMC6280891.
  7. Lee, NR, Gujarathi, S, Bommagani, S, Siripurapu, K, Zheng, G, Dwoskin, LP et al.. Muscarinic agonist, (±)-quinuclidin-3-yl-(4-fluorophenethyl)(phenyl)carbamate: High affinity, but low subtype selectivity for human M1 - M5 muscarinic acetylcholine receptors. Bioorg. Med. Chem. Lett. 2018; :. doi: 10.1016/j.bmcl.2018.12.022. PubMed PMID:30554957 .
  8. Ramírez, P, Garnacho-Montero, J. [Invasive aspergillosis in critically ill patients]. Rev Iberoam Micol. ;35 (4):210-216. doi: 10.1016/j.riam.2018.07.001. PubMed PMID:30554674 .
  9. Silva, IG, Silva, BSA, Freire, APCF, Santos, APSD, Lima, FF, Ramos, D et al.. Functionality of patients with Chronic Obstructive Pulmonary Disease at 3 months follow-up after elastic resistance training: a randomized clinical trial. Pulmonology. ;24 (6):354-357. doi: 10.1016/j.pulmoe.2018.09.005. PubMed PMID:30554670 .
  10. Li, S, Wang, G, Wang, C, Gao, X, Jin, F, Yang, H et al.. The REACH Trial: A Randomized Controlled Trial Assessing the Safety and Effectiveness of the Spiration® Valve System in the Treatment of Severe Emphysema. Respiration. 2018; :1-12. doi: 10.1159/000494327. PubMed PMID:30554211 .
Search PubMed
5/5 (1 Review)
SOMNAS.COM